DOCOSANOL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DOCOSANOL (DOCOSANOL).
Docosanol is a saturated fatty alcohol that inhibits fusion between the host cell plasma membrane and the herpes simplex virus envelope, thereby preventing viral entry and replication.
| Metabolism | Docosanol is metabolized via beta-oxidation to long-chain fatty acids; no significant cytochrome P450 metabolism. |
| Excretion | Docosanol is a topical agent with negligible systemic absorption; no significant renal or fecal elimination occurs after topical application. In animal studies, less than 1% of a topical dose was excreted in urine or feces as unchanged drug or metabolites. |
| Half-life | Due to negligible systemic absorption, a terminal elimination half-life is not defined for topical docosanol. In vitro studies of hepatic metabolism suggest a plasma half-life of approximately 1 hour if systemically absorbed, but clinical relevance is absent. |
| Protein binding | Docosanol is not significantly protein-bound due to minimal systemic absorption; in vitro data indicate binding to albumin and lipoproteins at <10%. |
| Volume of Distribution | Not applicable for topical use; if systemically absorbed (hypothetically), Vd would be expected to be >10 L/kg due to high lipophilicity, but no human data exist. |
| Bioavailability | Topical: Bioavailability is negligible (<1%) as docosanol acts locally on the skin and is not designed for systemic delivery. Oral bioavailability is not studied; the drug is not administered orally. |
| Onset of Action | Topical application: Healing of herpes simplex lesions typically begins within 1-2 days of initiating therapy, with full resolution in 4-6 days. Reduction in symptoms (itching, pain) may occur within hours. |
| Duration of Action | Topical: Application every 2-3 hours while awake for 5-10 days; the duration of action per dose is approximately 2-3 hours, corresponding to the dosing interval. Clinical benefit requires repeated application during prodrome and active lesion phase. |
Apply a thin layer of 10% cream to affected area 5 times daily until healing is complete, typically 4-6 days.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required. |
| Liver impairment | No dosage adjustment required. |
| Pediatric use | For children aged 12 years and older, same as adult dosing. Safety and efficacy in children under 12 years not established. |
| Geriatric use | No specific dosage adjustment recommended; use same dosing as for younger adults. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DOCOSANOL (DOCOSANOL).
| Breastfeeding | No data on excretion into breast milk; consider benefits of breastfeeding and importance of drug to mother. M/P ratio unknown. |
| Teratogenic Risk | No evidence of teratogenicity in animal studies; insufficient human data. Clinical use not associated with major malformations; risk cannot be excluded. First trimester: no documented fetal risk. Second and third trimesters: no adverse fetal effects reported. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to docosanol or any component of the formulation."]
| Precautions | ["Avoid application to mucous membranes (e.g., eyes, mouth, nose).","Do not use in immunocompromised patients without physician approval.","Discontinue if irritation or allergic reaction occurs."] |
Loading safety data…
| No specific fetal monitoring required. Observe for local skin reactions at application site. |
| Fertility Effects | No known effects on fertility in animal studies; no human data. |